protein

alpha-Synuclein 1-95, Human, Recombinant, E Coli

MBS203014

0.1 mg

255 USD

Recombinant Protein

alpha-Synuclein 1-95, Human, Recombinant, E Coli

alpha-Synuclein 1-95

SNCA; NACP; PARK1; alpha-Synuclein; Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; Alpha synuclein; Alpha-synuclein isoform NACP140; alphaSYN; MGC105443; MGC110988; MGC127560; MGC64356; Non A beta component of AD amyloid; Non A4 component of amyloid precursor; Non-A-beta component of alzheimers disease amyloid; precursor of PARK 1; PARK 4; PARK4; Parkinson disease familial 1; PD 1; PD1; Synuclein alpha

alpha-synuclein isoform NACP140; Alpha-synuclein; alpha-synuclein; non A-beta component of AD amyloid; synuclein alpha-140; synuclein, alpha (non A4 component of amyloid precursor); Non-A beta component of AD amyloid; Non-A4 component of amyloid precursor; NACP

SNCA; SNCA; PD1; NACP; PARK1; PARK4; NACP; PARK1; NACP

SYUA_HUMAN

140

MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVH GVATVAEKTK EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFV

> 95% by SDS - PAGE

Liquid in 20 mM Tris-HCl buffer (pH 7.5) containing 0.1 M NaCl

1 mg/ml (determined by BCA assay)

Can be stored at 4 degree C short term (1-2 weeks). For long term storage, aliquot and store at -20 degree C or -70 degree C. Avoid repeated freezing and thawing cycles.

SDS-PAGE

Antigen Species: Human

Expression System: E Coli

Neuroscience

A deletion mutant of alpha-synuclein (amino acids 1-95), which contains the N-terminal amphipathic domain and NAC region. alpha-synuclein 1-95 was overexpressed in E. coli and the recombinant protein was purified to apparent homogeneity by using conventional column chromatography techniques.

ueda K., et al. (1993) Proc. Natl. Acad. Sci. 90, 11282-11286. Jakes., et al. (1994) FEBS Letters 345, 27-32.

4507109

NP_000336.1

NM_000345.3

9.3 kDa (95 aa), confirmed by MALDI-TOF.

Alpha-synuclein Signaling Pathway (137913); Alzheimer's Disease Pathway (83097); Alzheimer's Disease Pathway (509); Alzheimers Disease Pathway (672448); Amyloids Pathway (366238); Disease Pathway (530764); EGFR1 Signaling Pathway (198782); Parkin-Ubiquitin Proteasomal System Pathway (700638); Parkinson's Disease Pathway (83098); Parkinsons Disease Pathway (705377)

Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene. [provided by RefSeq, Mar 2009]

SNCA: a member of the synuclein family. Abundantly expressed in the brain. Inhibits phospholipase D2 selectively. May integrate presynaptic signaling and membrane trafficking. Implicated in the pathogenesis of Parkinson s disease. A major component of amyloid plaques in the brains of patients with Alzheimer s disease. Two alternatively spliced isoforms transcripts have been identified. Protein type: Adaptor/scaffold. Chromosomal Location of Human Ortholog: 4q21. Cellular Component: Golgi apparatus; nuclear outer membrane; mitochondrion; rough endoplasmic reticulum; lysosome; extracellular region; fibril; terminal button; inclusion body; cell cortex; cytosol; mitochondrial respiratory chain complex I; actin cytoskeleton; platelet alpha granule membrane; synaptic vesicle; growth cone; perinuclear region of cytoplasm; axon; cytoplasm; plasma membrane; ribosome; nucleus; cell junction. Molecular Function: identical protein binding; protein domain specific binding; histone binding; zinc ion binding; kinesin binding; microtubule binding; ferrous iron binding; caspase inhibitor activity; beta-tubulin binding; magnesium ion binding; protein N-terminus binding; phosphoprotein binding; calcium ion binding; oxidoreductase activity; Hsp70 protein binding; dynein binding; protein binding; copper ion binding; phospholipase binding; phospholipid binding; fatty acid binding; tau protein binding; alpha-tubulin binding. Biological Process: regulation of long-term neuronal synaptic plasticity; negative regulation of serotonin uptake; regulation of acyl-CoA biosynthetic process; adult locomotory behavior; positive regulation of apoptosis; negative regulation of norepinephrine uptake; mitochondrial membrane organization and biogenesis; microglial cell activation; positive regulation of endocytosis; response to lipopolysaccharide; negative regulation of caspase activity; dopamine biosynthetic process; negative regulation of transcription from RNA polymerase II promoter; negative regulation of monooxygenase activity; fatty acid metabolic process; regulation of dopamine secretion; positive regulation of neurotransmitter secretion; negative regulation of dopamine uptake; negative regulation of histone acetylation; calcium ion homeostasis; response to magnesium ion; negative regulation of exocytosis; negative regulation of protein amino acid phosphorylation; behavioral response to cocaine; phospholipid metabolic process; receptor internalization; fibril organization and biogenesis; synapse organization and biogenesis; dopamine uptake; response to iron(II) ion; negative regulation of neuron apoptosis; positive regulation of receptor recycling; aging; caspase activation; response to drug; neutral lipid metabolic process; protein destabilization; regulation of macrophage activation; negative regulation of microtubule polymerization; regulation of glutamate secretion; positive regulation of peptidyl-serine phosphorylation; negative regulation of dopamine metabolic process; organelle ATP synthesis coupled electron transport; regulation of locomotion; synaptic vesicle endocytosis; positive regulation of release of sequestered calcium ion into cytosol; regulation of excitatory postsynaptic membrane potential; negative regulation of transporter activity; negative regulation of apoptosis. Disease: Parkinson Disease 4, Autosomal Dominant; Parkinson Disease 1, Autosomal Dominant; Dementia, Lewy Body

0.1 mg

255 USD

0.5 mg

535